Chimerix (NASDAQ:CMRX) Hits New 52-Week High – Should You Buy?

Shares of Chimerix, Inc. (NASDAQ:CMRX) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $8.48 and last traded at $8.47, with a volume of 1548851 shares. The stock had previously closed at $8.46.

Analysts Set New Price Targets

CMRX has been the subject of several research reports. Jefferies Financial Group reiterated a “hold” rating and set a $8.50 price objective (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. StockNews.com initiated coverage on Chimerix in a research note on Saturday. They issued a “hold” rating for the company. HC Wainwright reaffirmed a “neutral” rating and set a $8.55 target price (down previously from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, Wedbush reiterated a “neutral” rating and issued a $8.55 target price (up from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Stock Up 0.1 %

The stock has a 50-day moving average of $4.94 and a 200 day moving average of $2.64. The stock has a market cap of $761.76 million, a PE ratio of -9.01 and a beta of 0.32.

Insider Transactions at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the sale, the chief executive officer now owns 609,603 shares in the company, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 20,760 shares of company stock worth $91,175 in the last quarter. Company insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Bender Robert & Associates purchased a new stake in Chimerix in the fourth quarter valued at $37,000. Susquehanna Fundamental Investments LLC acquired a new position in Chimerix in the fourth quarter valued at about $59,000. Jane Street Group LLC purchased a new position in Chimerix during the fourth quarter worth about $62,000. Diadema Partners LP acquired a new stake in shares of Chimerix during the fourth quarter valued at about $101,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Chimerix during the fourth quarter valued at about $130,000. 45.42% of the stock is currently owned by hedge funds and other institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.